title: New treatment option: 223Ra chloride, the first approved unsealed α-emitting radiopharmaceutical.
abstract: A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases. After receiving 180 µCi (1.35 µCi/kg) of (223)Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat (223)Ra chloride administrations. (223)Ra chloride is the first Food and Drug Administration-approved unsealed α-emitting radiopharmaceutical.
authors.affiliation: University of Southern California, Los Angeles, CA, USA. colletti@usc.edu
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Colletti
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D017277:Drug Approval; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011883:Radium / Q000627:therapeutic use*
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; C581106:radium Ra 223 dichloride; D011883:Radium